Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
Date:11/9/2009

SAN DIEGO, Nov. 9, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the third quarter ended September 30, 2009.

Arena reported a lower net loss allocable to common stockholders in the third quarter of 2009 of $34.8 million, or $0.38 per share, compared to a net loss allocable to common stockholders in the third quarter of 2008 of $56.2 million, or $0.76 per share, and a net loss allocable to common stockholders in the first nine months of 2009 of $123.4 million, or $1.51 per share, compared to a net loss allocable to common stockholders in the first nine months of 2008 of $177.0 million, or $2.40 per share.

"The successful completion of the lorcaserin pivotal program in the third quarter was a critical milestone for Arena," stated Jack Lief, Arena's President and Chief Executive Officer. "The positive results were received with support and enthusiasm at The Obesity Society's annual meeting last month. Participating physicians shared with us three clear themes: the pressing need for new weight management treatments, the paramount importance of safety in treating overweight and obese patients, and that weight reduction should translate into improvements in cardiometabolic health. If approved, the unique combination of efficacy, safety and tolerability positions lorcaserin as first-line therapy."

As expected, research and development expenses declined significantly to $22.1 million in the third quarter of 2009 from $47.5 million in the third quarter of 2008. Research and development expenses declined to $89.0 million in the first nine months of 2009 from $151.0 million in the first nine months of 2008. This decrease is primarily due to the completion of the BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) and BLOSSOM (Behav
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Aethlon Medical, Inc. (OTCQB:AEMD), announced today that ... approximately $3.3 million at a price of $0.30 per ... focused investor. Each unit consists of one common share ... warrant. Each whole warrant entitles the holder to acquire ... a period of five years from closing.  ...
(Date:11/26/2014)...  Cohen, Placitella & Roth, PC is investigating ... Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 31, 2011 through November 2, 2014 ("Class Period").  ... its officers and directors publically disseminated materially false ... and 20(a) of the Securities Exchange Act of ...
(Date:11/26/2014)... Nov. 26, 2014 Lexicon Pharmaceuticals, Inc. ... completion of previously announced concurrent financing transactions resulting ... and estimated offering expenses, Lexicon anticipates net proceeds ... transactions consisted of: , a public ... to a registration statement that has been declared ...
Breaking Medicine Technology:Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
... 13-14, 2011, in Beijing, China, the Food and Drug Law ... drug law, regulation and policy in China and the United ... Commissioner, State Food and Drug Administration, Ambassador Zhang Yesui, Chinese ... at the meeting. Several U.S. government officials are expected to ...
... CHICAGO, Dec. 15, 2010 Allscripts MyWay ... -- deeming the Electronic Health Record (EHR) software capable ... use measures required to qualify for funding under the ... under the Drummond Group,s Electronic Health Records Office of ...
Cached Medicine Technology:Food and Drug Law Institute to Hold Historic Conference on U.S.-China Food and Drug Law 2Allscripts MyWay™ Electronic Health Record Receives ONC-ATCB Certification by Drummond Group 2Allscripts MyWay™ Electronic Health Record Receives ONC-ATCB Certification by Drummond Group 3Allscripts MyWay™ Electronic Health Record Receives ONC-ATCB Certification by Drummond Group 4Allscripts MyWay™ Electronic Health Record Receives ONC-ATCB Certification by Drummond Group 5
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded ... Holiday Event for those in the area that would like to ... & Glow will take place on December 11, 2014, from 6:00 ... heart of Houston at 4208 Richmond Ave. , “We want ... will come and celebrate the season with us on December 11, ...
(Date:11/28/2014)... Written and narrated by award winning author ... “The Happiest Man In the World: Life Lessons From ... and why Project C.U.R.E. came to be. , Raised in ... the Reverend Richard W. Jackson, Dr. Jackson exceeded his goal ... realized that he wasn’t happy. Prompted by this realization, James ...
(Date:11/28/2014)... Kramer HealthDay Reporter , THURSDAY, ... the kitchen, through cooking classes or at home, may make ... recent review. Cooking programs and classes for children seem ... the new research. And, although the review didn,t look at ... programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... An inventor and dental assistant from Kent, Wash., ... and it was almost impossible to reach. "This gave me ... , The patent-pending Access Light allows for easier use of ... the mouth, as well as avoids harm to the lips, ... use and clean, it also helps prevent cross-contamination. , The ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 More ... have now been filed in a New Jersey ... implants, Bernstein Liebhard LLP reports. , A ... County Superior Court reflects the filing of 2,160 ... hip stems, which were voluntarily recalled on July ...
Breaking Medicine News(10 mins):Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3
... techniques, the Chinese Tai chi and various relaxation techniques would ... on May 28 by the Rajayoga Foundation of Brahmakumaris of ... of the Medical wing of the foundation and a ... of physical ailments by discovering the spiritual potential of the ...
... research conducted by the King’s Collage London, analysed health reports of ... in 2003 with those who took part// in the 1991 war, ... ,The study findings that are published in The Lancet report ... Syndrome" in British male armed forces personnel deployed to the 2003 ...
... government is planning to bifurcate the Health and Family ... Health Services//. This step is thought to allow for ... Welfare Minister R Ashok said that the step was ... abuse the system. Initially the government will ask 23 ...
... conducted by the rheumotologists in the University of South ... form of Adkins-type diet for weight loss, has no ... the earlier findings conducted in animal studies. This finding ... issue of the journal Osteoporosis International. Low carbohydrate diets ...
... least six Reang refugees staying in camps in North Tripura ... HIV positive, official sources today here said. // ... in Kanchanpur subdivision by the state health department., ,The ... were found affected by AIDS and 12 as HIV positive, ...
... Ltd today said it would raise 16 million dollar through ... ,The company would allot 16,000 FCCBs of 1,000 ... listed on the Singapore Stock Exchange, Ankur Drugs informed the ... would be allotted 14,000 FCCBs while 1,000 FCCBs would be ...
Cached Medicine News:Health News:Good News For The Obese People 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 12 mm....
Medicine Products: